ERBB2 and breast carcinoma: Most previous studies based on US have achieved good prediction results for pCR prediction of breast cancer receiving NACT [40–42], but they are studies on all molecular subtyped breast cancers, and lack of comprehensive evaluation of each molecular subtyped breast cancer, especially for HER2-positive breast cancer with poor prognosis.